Tysabri and PML: What the Timeline of Symptoms Means for Patients

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specific Pharmaceutical Risk

If you or a loved one has been taking Tysabri and are now experiencing neurological changes such as confusion, weakness, or vision problems, you may be wondering how soon these symptoms could be linked to PML. Understanding the timeline of symptom onset is critical for early recognition and intervention. The medical community has long studied the relationship between Tysabri and PML, providing a foundation for current monitoring guidelines. This page explains what the PML warning means in practical terms and what patients and clinicians should watch for.

Medical Evidence Linking Tysabri to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Illinois who have developed PML after Tysabri treatment, understanding the medical evidence and legal considerations—including the statute of limitations—is critical. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus, which typically remains dormant in immunocompetent individuals but can reactivate in patients receiving immunosuppressive therapies. Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning emphasizes that these factors "should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication of the condition (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and visual changes. These symptoms overlap with those of multiple sclerosis, making diagnosis challenging. In the FDA Adverse Event Reporting System (FAERS), the most frequently reported adverse events associated with Tysabri include fatigue, multiple sclerosis relapse, headache, gait disturbance, memory impairment, and balance disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm causation, they highlight the range of neurological symptoms that may be reported in Tysabri-treated patients.

Mechanistic Pathways and Risk Considerations

The mechanistic link between Tysabri and PML involves the drug's action as an alpha-4 integrin antagonist. Tysabri blocks the adhesion of immune cells to the blood-brain barrier, reducing their migration into the central nervous system. This immunosuppressive effect is intended to reduce inflammation in multiple sclerosis but also impairs immune surveillance against the JC virus. In patients with anti-JCV antibodies, the virus can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic lesions of PML. The FDA boxed warning for Tysabri explicitly states the increased risk of PML and identifies the three known risk factors. However, questions may arise regarding the adequacy of these warnings in clinical practice. For example, whether patients were adequately informed about the risk of PML before starting treatment, whether anti-JCV antibody testing was performed and discussed, and whether monitoring for PML symptoms was conducted appropriately. The boxed warning also notes that Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which is designed to ensure that patients are informed of the risks and that healthcare providers follow monitoring protocols (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Legal Considerations for Illinois Patients

For patients in Illinois who have developed PML after Tysabri treatment, legal considerations include the statute of limitations for filing a product liability or medical malpractice claim. In Illinois, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. For wrongful death claims, the statute is also two years from the date of death. Given that PML can have a delayed onset and progressive course, the timeline between Tysabri exposure and documented harm is a critical factor. Patients or their families should consult with an attorney experienced in pharmaceutical litigation to determine the applicable deadlines and preserve their right to seek compensation. The risk of PML increases with longer Tysabri treatment duration, particularly beyond two years. However, PML can occur at any time during treatment, and cases have been reported after shorter durations. The latency period between JC virus reactivation and clinical symptoms can vary, and diagnosis often requires MRI imaging and cerebrospinal fluid analysis for JCV DNA. Once PML is diagnosed, the prognosis is poor, with most patients experiencing severe disability or death. The timeline from symptom onset to diagnosis and legal action is therefore variable and must be assessed on a case-by-case basis.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Illinois?

In Illinois, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered. For wrongful death claims, it is also two years from the date of death. Given the delayed onset of PML, it is crucial to consult an attorney promptly to determine the applicable deadline.

What are the known risk factors for developing PML while on Tysabri?

The FDA has identified three risk factors: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be considered when initiating and continuing Tysabri therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How is PML diagnosed in Tysabri-treated patients?

Diagnosis typically involves MRI imaging and cerebrospinal fluid analysis for JC virus DNA. Clinical symptoms such as progressive neurological deficits (weakness, gait disturbance, cognitive impairment) should prompt immediate evaluation. Tysabri should be withheld at the first sign of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.